A provider-focused update on Dronabinol availability in 2026. Shortage history, prescribing implications, cost considerations, and clinical tools.
Dronabinol (Marinol) — the synthetic delta-9-THC indicated for HIV/AIDS-related anorexia and refractory chemotherapy-induced nausea and vomiting — continues to present availability challenges for patients in 2026. While not currently listed on the FDA's official drug shortage database, real-world access remains inconsistent.
This briefing covers the current supply landscape, prescribing considerations, cost and access barriers, and practical tools to support your patients.
A documented supply disruption affected Dronabinol availability nationally. A retrospective observational study published in early 2025 found that chronic pain patients on Dronabinol were forced to discontinue treatment during this period, with measurable impacts on outcomes. The shortage was attributed to manufacturing and distribution constraints affecting the limited number of generic producers.
Syndros (dronabinol oral solution, 5 mg/mL), manufactured by Benuvia Therapeutics, was discontinued from the market. It now appears in the FDA's Discontinued Drug Product List. In July 2025, the FDA issued a formal determination that Syndros was not withdrawn for reasons of safety or effectiveness — a regulatory step that clears the path for potential ANDA filings for generic dronabinol oral solutions.
For now, this means the only commercially available Dronabinol formulations are soft gelatin capsules (2.5 mg, 5 mg, 10 mg) from brand Marinol (AbbVie) and generic manufacturers including Camber Pharmaceuticals and Par Pharmaceutical.
As of early 2026, Dronabinol is not on the FDA shortage list. However, providers and patients continue to report difficulty locating the medication at retail pharmacies — particularly at chain pharmacies that do not routinely stock controlled substances with lower prescription volumes.
Dronabinol capsules (Marinol and generics) are classified as DEA Schedule III. Prescriptions may be written or called in and may include refills (up to 5 refills within 6 months of the date written). This is less restrictive than Schedule II, which applies to some alternative medications like Nabilone (Cesamet).
Note that the now-discontinued Syndros oral solution was classified as Schedule II due to its different formulation and abuse potential profile.
HIV/AIDS-related anorexia:
Chemotherapy-induced nausea/vomiting (CINV):
The disconnect between the FDA's shortage database and actual pharmacy shelves comes down to several factors:
Medfinder for Providers can help your practice direct patients to pharmacies with current Dronabinol stock, reducing treatment delays and phone calls to your office.
Cost remains a significant barrier to Dronabinol access, particularly for uninsured or underinsured patients:
Medfinder allows you and your staff to quickly identify pharmacies with Dronabinol in stock near your patients. This can be integrated into your prescribing workflow to reduce callbacks and treatment delays.
For practices that handle high volumes of Dronabinol prior authorizations, consider using electronic prior authorization (ePA) through your EHR system. Key clinical criteria that insurers typically look for:
Direct your patients to these resources:
Several developments could improve Dronabinol access in the coming months:
When Dronabinol is unavailable, the following evidence-based alternatives may be appropriate depending on the clinical indication:
For a patient-facing overview of alternatives, see Alternatives to Dronabinol.
Dronabinol remains an important therapeutic option for a specific patient population, but access challenges persist in 2026. Proactive prescribing practices — including pharmacy verification through Medfinder, timely prior authorization submission, and familiarity with alternative agents — can help minimize treatment disruptions for your patients.
For provider-specific resources, including information on helping patients save on Dronabinol, see our provider's guide to Dronabinol cost savings.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
